Eating Almonds Before a Meal to Control Blood Sugar
Pennington Biomedical Research Center · NCT07603739
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 25–50 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 25
- US sites recruiting
- 1
- Study start
- June 23, 2026
- Record last updated
- July 17, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this study is to learn whether eating a small serving of almonds before meals can improve blood sugar control in adults who have early signs of problems with blood sugar regulation. The main questions it aims to answer are:
- Does eating almonds before a meal reduce the rise in blood sugar after eating?
- Do some people consistently benefit more than others from eating almonds before meals?
Being studied: Premeal almond ingestion
Conditions: Glucose Control; Prediabetes (Insulin Resistance, Impaired Glucose Tolerance); Precision Medicine; Nutrition
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Adults aged 25-50 years
- Females over 40 years must have had a cycle in the last 6 months
- Body mass index (BMI) at least 18.5 and at most 55.0 kg/m2
- Impaired blood glucose by at least one of the following criteria:
- Fasting blood glucose at least 100 mg/dL (5.6 mmol/L) and less than 125 mg/dL (6.9 mmol/L)
- HbA1c at least 5.7% and less than 6.5%
- Willing and able to comply with study foods
- Willing and able to ingest acetaminophen as part of study procedures
- Able to read, speak, and understand English
Exclusion Criteria
- Weight change ≥5% in past 6 months, actively trying to lose weight, or unwilling to remain weight stable throughout the study based on self-report
- Recent history within past 12 months of medical provider-diagnosed cardiovascular, renal, or liver disease that required treatment
- Current or past diagnosis of cancer (except skin cancer) in the last 5 years
- Current or past diagnosis of type 1 or type 2 diabetes
- Recent history within past 12 months of medical provider-diagnosed gastrointestinal or neurological disorders if not managed/stable for at least 3 months (with or without treatment)
- Recent history within past 12 months of medical provider-diagnosed psychiatric disorders including eating disorders or severe depression if not managed/stable for at least 3 months (with or without treatment)
- Food allergies or other reasons preventing consumption of study foods
- Any glucose-lowering medication except biguanides (e.g., Metformin) if stable for at least 3 months or incretins (i.e., GLP-1RA-based) if stable for at least 3 months
- Current smoking or vaping or history of smoking or vaping in the past 6 months
- Binge and/or heavy drinking (i.e., >3 drinks on any given occasion and/or >7 drinks/week)
- Currently pregnant or planning to become pregnant or breastfeed in the next 3 months by self-report
Recruiting US locations
Pennington Biomedical Research Center
Baton Rouge, LA 70808
Site contact: Kaja Falkenhain, PhD · 225-763-2558 · kaja.falkenhain@pbrc.edu
Study contacts (from the official record)
- Kaja Falkenhain, PhD · 225-763-2558 · kaja.falkenhain@pbrc.edu
Similar studies in Louisiana
All diabetes studies in Louisiana →- RecruitingHealthy volunteers
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Cleerly, Inc.
- Location
- New Orleans, LA + 121 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Baton Rouge, LA + 57 other US sites
- Eligibility basics
- Ages 18–80
- Recruiting
The RESET System Pivotal Clinical Trial (Protocol Revision K)
Morphic Medical Inc.
- Location
- Lake Charles, LA + 25 other US sites
- Eligibility basics
- Ages 22–65
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- New Orleans, LA + 43 other US sites
- Eligibility basics
- Ages 18+